The U.S. Food and Drug Administration has expanded the approval of Bristol Myers Squibb (opens in new tab)’s Camzyos (mavacamten) to include pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy who weigh at least 30 kilograms (about 66 pounds), the company announced Sept. 30. Camzyos was first approved for adults in 2022. BMS says it is now the only FDA-approved therapy for obstructive HCM in a pediatric population.
Hypertrophic cardiomyopathy is the most common inherited heart disorder; in the obstructive form, thickened heart muscle obstructs the left ventricular outflow tract (LVOT). Children with the condition face risks including ventricular arrhythmias, heart failure and atrial fibrillation, according to BMS. The pediatric approval rests on SCOUT-HCM, a Phase 3 randomized, double-blind, placebo-controlled trial in 44 patients ages 12 to 17. Camzyos reduced the Valsalva LVOT gradient at 28 weeks by 48.0 mm Hg more than placebo, according to BMS and AJMC (opens in new tab). No patient had left-ventricular ejection fraction fall below 50%, no adverse events led to discontinuation, and serious adverse events occurred in two patients in each group.
Joseph W. Rossano, chief of cardiology at Children’s Hospital of Philadelphia and chair of the SCOUT-HCM steering committee, told Healio (opens in new tab), “This is the first time that we have an FDA-approved medication that is specifically designed for the treatment of cardiomyopathy in children.” He added that long-term follow-up of pediatric patients is still needed. Rossano reports consulting for BMS.
Camzyos carries a boxed warning for heart failure risk. Echocardiogram checks of heart function are required before and during treatment, and the drug is available only through a restricted REMS program. In adult trials, dizziness and fainting were more common with Camzyos than with placebo; BMS said SCOUT-HCM identified no new adverse reactions in adolescents.